Sign in

Ed Wu

Research Analyst at Ascendiant Capital

Edward M. Woo, CFA, is Director of Research and Senior Analyst at Ascendiant Capital Markets, specializing in equity research with a focus on industry and company analysis, financial modeling, and investment recommendations. Over his eight years at Ascendiant, Mr. Woo has covered numerous publicly traded companies, delivering investment insights supported by extensive experience and a proven track record, including media appearances on CNBC and Bloomberg, and quotes in Reuters and MarketWatch. Woo began his analyst career more than twenty years ago, formerly serving as an equity analyst at Wedbush Securities and holding roles at PricewaterhouseCoopers, Unisys Corporation, and Atlantic Richfield Company prior to joining Ascendiant. He holds a Yale MBA, is a Chartered Financial Analyst and California licensed CPA (inactive), and maintains FINRA Series 7, 16, 24, 63, 86, 87, and 99 registrations.

Ed Wu's questions to AYTU BIOPHARMA (AYTU) leadership

Question · Q4 2025

Ed Wu requested clarification on Aytu BioPharma's pro forma operating expenses of $39 million and the planned distribution of the $10 million additional investment for the Exua launch throughout the fiscal year.

Answer

CFO Ryan Selhorn clarified that the pro forma annual operating expense is about $36.3 million, with the $10 million Exua launch investment starting in the December quarter (Q2 fiscal 2026). He estimated that approximately 50% of this investment would be spent in Q2, with the remaining 50% distributed across Q3 and Q4, primarily covering sales representatives and marketing materials.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts